Vernal keratoconjunctivitis (VKC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Vernal keratoconjunctivitis (VKC) Market Outlook

Thelansis’s “Vernal keratoconjunctivitis (VKC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vernal keratoconjunctivitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Vernal keratoconjunctivitis (VKC) Overview

Vernal keratoconjunctivitis (VKC), characterized by chronic bilateral seasonal allergic inflammation of the ocular tissues, represents a significant contributor to visual impairment and reduced quality of life, particularly affecting children and young adults in specific geographical regions such as the Mediterranean, Central and West Africa, the Middle East, Japan, the Indian subcontinent, and South America. While VKC commonly follows a self-limiting trajectory, a subset of cases displays recurrent patterns leading to enduring visual complications like keratoconus and limbal stem cell deficiency. Immunoglobulin E-mediated mechanisms predominantly underlie its pathogenesis, although non-immunoglobulin E pathways and nonspecific hypersensitivity mechanisms may also contribute. Key cellular participants include CD4 T cells and eosinophils. Managing VKC poses notable challenges, with acute episodes often manageable using topical agents currently available. However, preventing recurrences and mitigating associated sequelae pose considerable obstacles. Steroids demonstrate efficacy in acute and chronic phases, yet adverse effects hinder their prolonged use. Immunomodulators like tacrolimus and cyclosporine serve as alternatives to steroids, aiming to reduce reliance on the latter; however, optimal dosing and duration remain undetermined. Surgical interventions become necessary to address complications such as shield ulcers, corneal ectasia, or opacity. Despite considerable understanding of the disease process and management, gaps persist in elucidating genetic predispositions to chronicity and developing safe, effective long-term treatment modalities for chronic VKC, warranting further investigation.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: